It has been known since 1867 that organic nitrates are effective in relieving pain in angina pectoris, and nitroglycerin was prescribed for this indication even to Alfred Nobel. 1 Subsequently, it has been used for a century without anyone knowing its mechanism of action. Thanks to the work of Furchgott, Ignarro and Murad, who shared the 1998 Nobel Prize in physiology or medicine, we know that nitrodilators release nitric oxide (NO), either spontaneously or through an enzymatic process. 2 NO diffuses into the smooth muscle cell layer, where it activates soluble guanylyl cyclase (sGC) to form cyclic guanosine monophosphate (cGMP). Increased intracellular cGMP reduces calcium influx, increases cell hyperpolarisation by activating potassium channels, and promotes dephosphorylation of myosin light chains, resulting in smooth muscle relaxation. When nitrates are given at therapeutic doses, the main effect is venous dilation, which reduces ventricular preload. 3 This reduces ventricular wall stress and oxygen demand by the heart, thereby enhancing the oxygen supply/demand ratio. Lower diastolic wall stress also helps improve subendocardial blood flow, which is often compromised in coronary artery disease (CAD). Mild to moderate coronary dilation even in the presence of atherosclerotic plaque and/or reversal of coronary vasospasm further increases the oxygen supply/demand ratio. This process takes place primarily in the large epicardial vessels, thus diminishing the likelihood of coronary vascular steal. Systemic arterial dilation reduces afterload, which can enhance cardiac output while reducing ventricular wall stress and oxygen demand. 4 Endogenous NO is synthesised by three isoforms of nitric oxide synthase (NOS) encoded by distinct genes: inducible NOS (iNOS), brain or neuronal NOS (nNOS) and endothelial NOS (eNOS). 5 The inducible isoform (iNOS) is mainly regulated through gene transcription following pro-inflammatory and oxidative stress conditions, while the constitutively expressed nNOS and eNOS are highly regulated by transcriptional, post-transcriptional and post-translational mechanisms. 5 eNOS is a 1203 amino acid, 133 kDa protein encoded by the NOS3 gene, located on chromosome 7 in humans. In the cardiovascular system, eNOS is principally expressed in endothelial cells, 6 but also in cardiomyocytes and platelets. 5 Shear stress and reactive oxygen species are well known activators of eNOS mRNA synthesis through transcription factors such as nuclear factor kB and Kru¨ppel-like factor 2, or oxidant-responsive kinases. 7, 8 Furthermore, eNOS expression is influenced by polymorphisms of the eNOS gene as detailed below, and is also regulated through DNA methylation and by several microRNAs. The localisation and activity of the eNOS protein is finely tuned through post-translational mechanisms, such as phosphorylation, acetylation, etc. 9, 10 Finally, enzyme uncoupling may affect NO production, and NO may be inactivated by oxidative stress, while sGC activity may be reduced through oxidation. The ultimate consequences of altered eNOS/NO signalling are disruption of cardiovascular homeostasis, including endothelial dysfunction, possibly leading to the development of atherosclerotic plaques. 11 These considerations provide a conceptual framework for assessing eNOS with regard to the risk of CAD evolution, to which other studies recently published may add detail. [12] [13] [14] In the present issue of the journal, Li and colleagues provide a systematic review and meta-analysis of 132 studies assessing the relationship between genetic variants in NOS3, coding for eNOS, and the risk of CAD. 15 Among 12 gene variants, the rs891512, rs1799983, rs2070744, rs11771443 and rs869109213 polymorphisms displayed a significant association with CAD. Among them, three (rs1799983, rs2070744 and rs869109213) significantly correlated with the risk of myocardial infarction and acute coronary syndrome. Furthermore, two variants (rs1799983 and rs2070744) appeared relevant in both Caucasians and Asians and the rs869109213 polymorphism in Caucasians. The authors conclude that the five polymorphisms above (rs891512, rs1799983, rs2070744, rs11771443 and rs869109213) may serve as genetic biomarkers of CAD. 15 The authors should be congratulated for their effort to summarise the available evidence from case-control studies on eNOS polymorphisms and the risk of CAD. Nonetheless, the gene variants assessed derived from studies comparing patients with CAD to healthy controls; therefore, a cumulative assessment of the studies assessing each polymorphism would necessarily demonstrate an association between that variant and the risk of CAD, with a level of significance likely to be affected by the number of studies considered (ranging from one to 87). 15 From a pathophysiological perspective, we may also consider that a single gene was evaluated, although the expression and function of eNOS is regulated through a plethora of mechanisms, as summarised above. Furthermore, the authors evaluated just five polymorphisms in this gene, two of them (rs891512 and rs11771443) deriving from single studies. On the whole, isolated polymorphisms selected through this approach might not prove useful biomarkers in clinical practice, especially in complex and multifactorial conditions such as CAD. Genome-wide association studies (GWASs) would represent more accurate and reliable tools to define the molecular profiles making an individual more susceptible to CAD, including (but not being limited to) the eNOS/NO pathway.
GWASs basically consist in unbiased large-scale population-based studies evaluating the association of hundreds of thousands of markers (generally single nucleotide polymorphisms) across the genome with a particular phenotype. 16, 17 These studies are not hypothesis driven, allowing the discovery of novel genetic markers. However, GWASs are not without challenges and limitations and they must be carefully designed and executed. For example, it is important to keep phenotypic heterogeneity of cases and misclassification of controls to a minimum. Cases and controls should be well matched to avoid confounders, such as population stratification. Furthermore, sample sizes should be large, generally in the thousands, and replication sample sizes in an independent population should be even larger. The risk of false positive or spurious associations is high in GWASs, and strict quality control is essential. If these prerequisites are met, GWASs may represent powerful tools to stratify patient prognosis, dissect the mechanisms of disease and possibly discover new therapeutic targets. 16, 17 So far, a few GWASs have identified gene variants in the eNOS/NO pathway as predictors of CAD. More precisely, a GWAS metaanalysis of approximately 185,000 CAD cases and controls, interrogating 6.7 million common and 2.7 million low-frequency variants, has associated the rs3918226 variant of the NOS3 gene, previously characterised as predictive of essential hypertension, with the risk of CAD. 18 Notably, this variant was not considered in the study by Li and colleagues. 15 There is also evidence that a polymorphism in the promoter of the NOS3 gene influences the expression of eNOS with a negative effect of the risk allele. The effects on CAD risk also seem larger than expected from an effect on blood pressure only. 19 Furthermore, a subunit of sGC (GUCY1A3) was shown to harbour a common variant associated with CAD. 20 Even more evidence comes from the detection of a rare loss-offunction variant identified in an extended family with a high prevalence of premature CAD and myocardial infarction, in which exome sequencing identified a mutation in GUCY1A3 to be responsible for the phenotype. 21 Furthermore, mice lacking the a1-subunit of the sGC have been shown to display accelerated thrombus formation. 21 To summarise, searching for gene variants associated with the risk of CAD is worthwhile, as it may provide further tools to stratify patient risk. On the other hand, systematic reviews and meta-analyses based on case-control studies may not represent the optimal tool to identify such variants. Several GWASs have already suggested the involvement of the eNOS/NO pathway in the development of CAD, but further such studies and an in-depth characterisation of the functional consequences of the gene variants identified are warranted. Finally, a distinction between stable CAD and acute coronary syndrome, whose pathophysiology differs markedly, should be pursued.
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